Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | ADRB3 | P13945 | 7/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.54 |
| ▸ | AR | P10275 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11247517 | 1.00 | PTGS1 (0.59) | PTGS1SLC6A2ADRB3ADRB2ADRB1 | |
| SCHEMBL10492919 | 0.98 | PTGS1 (0.57) | PTGS1SLC6A2ADRB3ADRB2ADRB1 | |
| SCHEMBL27684651 | 0.94 | MAOA (0.54) | PTGS1SLC6A2ADRB3ADRB2ADRB1 | |
| SCHEMBL15500156 | 0.94 | PTGS1 (0.54) | PTGS1SLC6A2ADRB3ADRB2ADRB1 | |
| SCHEMBL6228324 | 0.91 | AR (0.61) | ARTSHRMAPK1LMNAMAPT | |
| SCHEMBL24369885 | 0.91 | BACE1 (0.59) | PTGS1SLC6A2ADRB3ADRB2ADRB1 | |
| SCHEMBL26326569 | 0.91 | SLC6A2 (0.51) | PTGS1SLC6A2ADRB3ADRB2ADRB1 | |
| SCHEMBL10490309 | 0.89 | PTGS1 (0.65) | PTGS1SLC6A2ADRB3ADRB2ADRB1 | |
| SCHEMBL10492789 | 0.89 | PTGS1 (0.65) | PTGS1SLC6A2ADRB3ADRB2ADRB1 | |
| SCHEMBL16226561 | 0.87 | AR (0.76) | PTGS1SLC6A2ADRB3ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7300413-A | — | — | None | — | — | JP | disclosed |
| US-11530149-B2 | Recycling of alkali sulfate rich waste water by biological pre-treatment with an extreme halophilic organism | COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) | 2022-12-20 | — | — | US | disclosed |
| US-20210053855-A1 | RECYCLING OF ALKALI SULFATE RICH WASTE WATER BY BIOLOGICAL PRE-TREATMENT WITH AN EXTREME HALOPHILIC ORGANISM | COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) | 2021-02-25 | — | — | US | disclosed |
| CN-105153146-A | Novel 3-hydroxyisothiazole 1-oxide derivative | MOCHIDA PHARM CO LTD | 2015-12-16 | — | — | CN | disclosed |
| CN-103517898-B | Novel 3-hydroxyisothiazole 1-oxide derivatives | MOCHIDA PHARMACEUTICAL CO.,LTD. (JP) | 2015-09-30 | — | — | CN | disclosed |
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-9072758-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| CN-104710381-A | Novel 3-hydroxy-5-arylisothiazole derivative | MOCHIDA PHARM CO LTD | 2015-06-17 | — | — | CN | disclosed |
| US-9040525-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-4329289-A | Adrenergic blocking agents | HOFFMANN-LA ROCHE INC. (US) | 1982-05-11 | — | — | US | disclosed |
| US-4314085-A | Intermediates for preparing adrenergic blocking agents | HOFFMANN-LA ROCHE INC. (US) | 1982-02-02 | — | — | US | disclosed |
| US-4304721-A | Adrenergic blocking agents | HOFFMANN-LA ROCHE INC. (US) | 1981-12-08 | — | — | US | disclosed |
| US-4301300-A | ADRENERGIC BLOCKING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1981-11-17 | — | — | US | disclosed |
| US-4285873-A | ANTIANDROGENS | HOFFMANN-LA ROCHE INC. (US) | 1981-08-25 | — | — | US | disclosed |
| US-4281189-A | Sulfonamide intermediates for adrenergic blocking agents | HOFFMANN-LA ROCHE INC. (US) | 1981-07-28 | — | — | US | disclosed |
| US-4278608-A | Adrenergic blocking agents | HOFFMANN-LA ROCHE INC. (US) | 1981-07-14 | — | — | US | disclosed |
| US-4247710-A | THE 3'-HYDROXY, -BENZYLOXY, OR -HALO DERIVATIVES OF METHYL 4-((2'-HYDROXYPROPYL)OXY)PHENYLACETATE | HOFFMANN-LA ROCHE INC. (US) | 1981-01-27 | — | — | US | disclosed |
| US-4202978-A | ADRENERGIC BLOCKING AGENTS, HYPOTENSIVE, ANTISECRETORY, SPASMOLYTIC | HOFFMANN-LA ROCHE INC. (US) | 1980-05-13 | — | — | US | disclosed |
| EP-0005142-A1 | Phenylpiperazine derivatives, process for their preparation, intermediates for this purpose and medicaments containing such phenylpiperazine derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR4A1 | PTGS1 2540/4885SLC6A2 3726/4885ADRB3 206/4885 |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | PTGS1 2589/4885SLC6A2 3350/4885ADRB3 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.